This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk00: Greetings. Welcome to the ExoBionics first quarter 2022 financial results call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. Please note this conference is being recorded. I will now turn the call over to your host, Andrew Blazier of Finn Partners. Thank you. You may begin.
spk02: Thank you, Devin, and thank you all for participating in today's call. Joining me from Exobionics are Stephen Sherman, Chairman and Chief Executive Officer, Scott Davis, President and Chief Operating Officer, and Jack Glenn, Chief Financial Officer. Earlier today, Exobionics released financial results for the first quarter ended March 31, 2022. A copy of the press release is available on the company's website. Before we begin, I would like to remind you that management will make statements during this call that include forward-looking statements within the meaning of the federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that are not statements of historical facts should be deemed to be forward-looking statements. All forward-looking statements, including statements regarding our business strategy, future financial or operational expectations, or our expectations of the regulatory landscape governing our products and operations are based upon management's current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. For a list and description of the risks and uncertainties associated with our businesses, please see our filings with the Securities and Exchange Commission. EXO disclaims any intention or obligation except as required by law to update or revise any financial or operational projections our regulatory outlook, or other forward-looking statements, whether because of new information, future events, or otherwise. This conference call contains time-sensitive information and is accurate only as of the broadcast today, April 28, 2022. I will now turn the call over to Exobionics Chairman and CEO, Stephen Sherman.
spk03: Thank you, Andrew, and thank you, everyone, for joining us today. We're off to a strong start in 2022. Revenues in the first quarter are up by more than 30% year over year, and we are seeing momentum in both our ExoHealth and our ExoWorks business segments. Our customers recognize the value and benefits that wearable exoskeletons bring to both patients and essential workers. Our balance sheet remains strong. We are focused. We have a cohesive team of professionals and our products continue to be leading edge and innovative. We are executing our strategy of deepening relationship with network operators, expanding our presence in industrial markets, and strengthening the foundation of the business to drive shareholders' value. Now, I will turn the call over to our President and Chief Operating Officer, Scott Davis.
spk05: Thank you, Stephen. After coming off a record fourth quarter, we begin 2022 with a strong first quarter. Supported by a solid focus in execution on our commercial strategy, we achieved year-over-year revenue growth of 34%. During the quarter, XO Health delivered $1.9 million of revenue as we continued to gain traction with network operators. We booked several multi-unit orders for our XO and our XO skeleton devices. including our largest order in company history, as network operators are choosing to make XONR their standard of care in neurological rehabilitation. This was a noteworthy achievement for the XO Health team. It clearly demonstrates the value our customers see in the XONR in rehabilitating patients from stroke, spinal cord, and traumatic brain injury. We recorded 23 XONR bookings in the quarter, with most being capital purchases. 10 of which are included in our second quarter backlog. This, in combination with our existing ExoHealth orders, is estimated to contribute to revenues over the next several months. Our cumulative conversion and renewal rate is 82%, and we now have more than $1.5 million of contracted, unrecognized revenue under our subscription model. We're seeing a strong rebound in post-COVID capital purchases. In addition, customers continue to utilize our flexible commercial offerings. For example, another top tier network operator adopted a new subscription program, which opens up opportunities for the placement of additional units in the future. In the international market, Europe continues to perform well. Increased proficiencies in our sales process are driving more opportunities. In APAC, we are building a healthy pipeline that should contribute to future revenue growth. We are optimistic about both Europe and APAC, which we expect to be important growth drivers throughout the year. The global supply chain remains a challenge, impacting product delivery times and adding cost pressure. Our operations team continues to navigate these obstacles to ensure consistent product shipments. Still, we experienced delays in the first quarter, and as a result, some orders were pushed to the second quarter. Today, we'd like to share a story of one of our newest customers the first facility to bring XONR to the island of Maui. Venture Physical Therapy is renowned in the medical community of Maui for its expertise in complex cases, including severe stroke and acquired brain injury. Venture PT was gifted XONR from a local patient, Sharon, who was first able to use XO at Craig Hospital in Colorado and QLI in Nebraska after sustaining a traumatic brain injury related to an accident. After seeing success with EXO and inpatient rehab, she wanted to continue using the technology in outpatient care in her home state of Hawaii. Now, thanks to Sharon and her family, more patients in Maui will have access to our life-changing technology. Turning to an update on progress with our industrial segment, EXO Works. Increasing numbers of employers are realizing the workplace productivity and safety benefits of EVO, our upper body exoskeleton. ExoWorks delivered approximately $700,000 of revenue during the quarter. This included a number of new and repeat orders, primarily in the automotive and aerospace verticals. In addition to this positive momentum, we are encouraged by increasing interest from both construction and general manufacturing markets. All told, our target industrial verticals represent a vast opportunity. We are working to deepen adoption within this still nascent $5 billion addressable market. As we look ahead, we remain cautiously optimistic, but are monitoring global events as pockets of increases in COVID cases have been reported recently, particularly in areas of Europe and Asia. Nevertheless, we're making great progress with customer engagement, thanks to our excellent commercial team. We look forward to additional successes in the coming months. At this time, I'd like to turn the call over to our CFO, Jack Glenn, to review our first quarter financial results.
spk04: Thank you, Scott. EXO generated first quarter 2022 revenue of $2.6 million compared to $1.9 million for the first quarter of 2021, a 34% increase. The increase in revenue was primarily driven by higher EVO sales and recognition of prepaid royalties associated with a license and distribution agreement. Our gross profit for the first quarter was $1.2 million, representing a gross margin of approximately 47% compared to gross margin of 65% for the same period a year ago. The overall decrease in gross margin was primarily due to an increase in ExoHealth service costs, changes in product mix, and an increase in material costs due to supply chain pressure, partially offset by the aforementioned recognition of prepaid royalties. As we've noted on previous calls, Gross margin tends to fluctuate from quarter to quarter based on channel and product mix, as was the case this quarter. Operating expenses for the first quarter of 2022 were $5.4 million compared to $4.4 million for the first quarter of 2021. During the first quarter of 2022, the company incurred increased general and administrative expenses related to higher cash and non-cash compensation expenses and severance expense. Research and development expenses increased in the first quarter due to an increase in product development activities. Net operating loss in the first quarter of 2022 was $4.2 million compared with a net operating loss of $3.1 million in the prior year period. Loss on warrant liabilities for the quarter ended March 31st, 2022 was $100,000 from the revaluation of warrants issued in 2019 2020 and 2021 compared to a de minimis gain associated with the revaluation of warrants issued in 2019, 2020 and 2021 for the same period in 2021. Cash used in operating activities in the first quarter of 2022 was $4.2 million. As of March 31st, 2022, the company had a strong cash balance of $36.2 million. Please see our 10-Q filed earlier today for further details regarding the quarter. Operator, you may now open the line for questions.
spk00: Thank you. We will now be conducting a question and answer session. If you would like to ask a question, please press star 1 on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press star 2 if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up the handset before pressing the star keys. One moment, please, while we poll for questions. Our first question comes from the line of RK with HC Wainwright. Please proceed with your question.
spk01: Thank you. Good afternoon, folks. Thanks for doing the call, and I'm glad to see the continued growth in both segments of the business. But my two questions today are specifically on the XO health business. So for the first quarter, you recorded $1.9 million, which is quite close to the numbers that we saw in the second quarter of 21. Can you help us understand your enthusiasm for this segment And also, you know, the potential growth that you're seeing because you made some commentary regarding how your strategy is working. So I just want to understand if you can expand and help us understand what you mean by that statement.
spk05: Okay, thank you. This is Scott Davis. I certainly appreciate the question and you joining today. With our global health business, we are continuing to see growth as more and more large network operators are adopting EXO as part of their programs. They're using this, and we're seeing many multi-unit orders that are coming in as they are using this as more of a standard of care program. The work of our commercial team as well as our clinical team in offering the training and support to these organizations is really causing a significant growth. Additionally, we are seeing some of the capital budgets open up that have been previously restricted by COVID, so we are definitely seeing a strong increase in the demand both for our capital purchases as well as in the uptake of our subscription program.
spk01: Okay. And then you stated 23 and ours being booked during the first quarter. So what went into the mix for that $1.9 million of that 23? And also you stated that one point, I believe this is, please correct me if I'm wrong, 1.3 million potential sales are out there based on the number of units which are under subscription at this point. So over what period are you thinking about in terms of recognition of this 1.3 million potential? And are the recent units that came onto subscription let's say within the last three months or six months. I'm just trying to figure out how would I think about this 1.3 million potential.
spk05: Yeah, so I think your question maybe relates to the mix between capital and subscription and then further the revenue recognition on those placed orders. Yeah, partially. Okay, so with respect to that, The mix on the 23 orders was really a good blend. We were close to a balance between them, close to a 50-50 match between subscription and capital purchases in Q1. Again, this has driven backlog for us, and we expect to be... shipping on those units throughout Q2. And as we continue to sell, we expect to also continue a small backlog as we move into Q3.
spk01: Okay. And then what were the number of units that were really placed during the Q1? Number, I'm sorry, number of units that were placed either in subscription model or capital purchases, yeah.
spk04: Total shipments was nine units for the quarter.
spk01: Okay.
spk04: Okay, perfect. So we have, as Scott mentioned, we have a significant, you know, based off of that, again, you know, fairly significant backlog as we've talked about going forward for Q2 as well as in the Q. Okay.
spk01: Okay. Okay, so I got it. So it's nine units placed and 14 units yet to be placed.
spk05: Is that how I should think about it? That's right. They were carried over and we also came into Q1 with an existing backlog as well. So as we continue to work through these supply chain challenges, we expect a significant increase in the number of units that we'll be shipping going through Q2 and into Q3.
spk01: Perfect. Thank you very much for that.
spk05: Thank you.
spk00: Thank you. We have no further questions at this time. I'd like to turn the floor back over to management for closing comments.
spk05: Thank you, Devin, and thanks to everyone for joining us today. Our first quarter revenue performance reflects the positive strides we've made to increase customer engagement for our innovative products. We're excited about the progress we are making at Exobionics as our commercial strategy continues to reward in the form of increased bookings, resulting in strong revenue growth. We are successfully meeting at the supply chain challenges of our current environment by delivering to our customers and patients. Looking ahead, we will continue to execute on our strategy of strengthening relationships with our top network operators, increasing order flow through a strong pipeline, and expanding EVO sales by capturing new customers across a variety of industry verticals. We are grateful for the continued contributions of the entire XO team, and we look forward to providing additional updates throughout the year. Thank you, and have a great day.
spk00: This concludes today's teleconference. You may disconnect your lines at this time. Thank you for your participation and have a wonderful day.
Disclaimer